← Back to Screener
TuHURA Biosciences, Inc. Common Stock (HURA)
Price$2.96
Favorite Metrics
Price vs S&P 500 (26W)13.64%
Price vs S&P 500 (4W)57.48%
Market Capitalization$195.19M
All Metrics
Book Value / Share (Quarterly)$0.33
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.68
Price vs S&P 500 (YTD)302.91%
EPS (TTM)$-1.55
10-Day Avg Trading Volume1.77M
EPS Excl Extra (TTM)$-1.55
EPS (Annual)$-1.16
Dividend / Share (Annual)$0.00
ROI (Annual)-148.57%
Cash / Share (Quarterly)$0.05
ROA (Last FY)-108.59%
EBITD / Share (TTM)$-0.97
ROE (5Y Avg)-586.18%
Cash Flow / Share (Annual)$-0.35
P/B Ratio11.63x
P/B Ratio (Quarterly)7.58x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-4.30x
ROA (TTM)-180.41%
EPS Incl Extra (Annual)$-1.16
Current Ratio (Annual)3.68x
Quick Ratio (Quarterly)0.40x
3-Month Avg Trading Volume1.46M
52-Week Price Return-26.90%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.17
52-Week High$4.44
EPS Excl Extra (Annual)$-1.16
26-Week Price Return17.62%
Quick Ratio (Annual)3.68x
13-Week Price Return329.37%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.40x
Enterprise Value$192.982
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.30
3-Month Return Std Dev198.57%
Net Income / Employee (TTM)$-2
ROE (Last FY)-148.57%
Net Interest Coverage (Annual)-4.96x
EPS Basic Excl Extra (Annual)$-1.16
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-1.55
ROI (TTM)-277.98%
Dividend Growth Rate (5Y)-52.55%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-56.73%
Year-to-Date Return305.55%
5-Day Price Return56.63%
EPS Normalized (Annual)$-1.16
ROA (5Y Avg)-207.15%
Month-to-Date Return71.51%
EBITD / Share (Annual)$-0.94
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-586.18%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.55
P/TBV (Quarterly)14.92x
P/B Ratio (Annual)12.08x
Dividend / Share (TTM)$0.00
Book Value / Share (Annual)$0.34
Price vs S&P 500 (13W)328.68%
Dividend Yield (TTM)0.00%
Beta0.20x
Revenue / Share (TTM)$0.00
ROE (TTM)-282.22%
52-Week Low$0.41
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HURATuHURA Biosciences, Inc. Common Stock | — | — | — | — | $2.96 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
TuHURA Biosciences is an immuno-oncology company advancing a personalized cancer vaccine candidate, IFx-2.0, designed to overcome primary resistance to checkpoint inhibitor immunotherapy. The company is preparing to initiate a Phase 3 registration trial evaluating IFx-2.0 in combination with Keytruda (pembrolizumab) as a first-line treatment for advanced or metastatic Merkel Cell Carcinoma.